Literature DB >> 11472458

Elevated matrix metalloproteinase-2 and -9 in urine, but not in serum, are markers of type 1 diabetic nephropathy.

M Diamant, R Hanemaaijer, J H Verheijen, J W Smit, J K Radder, H H Lemkes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11472458     DOI： 10.1046/j.1464-5491.2001.00476-2.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN： 0742-3071            Impact factor:   4.359


× No keyword cloud information.
  10 in total

Review 1.  Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic?

Authors:  Caroline B Marshall
Journal:  Am J Physiol Renal Physiol       Date:  2016-08-31

2.  Urinary matrix metalloproteinase activities: biomarkers for plaque angiogenesis and nephropathy in diabetes.

Authors:  Ian B McKittrick; Yolanda Bogaert; Kristen Nadeau; Janet Snell-Bergeon; Amber Hull; Tao Jiang; Xiaoxin Wang; Moshe Levi; Karen S Moulton
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-14

3.  Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy.

Authors:  Kyoichi Tashiro; Ichiro Koyanagi; Ikko Ohara; Takamichi Ito; Akemi Saitoh; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

Review 4.  Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy.

Authors:  Kathryn M Thrailkill; R Clay Bunn; John L Fowlkes
Journal:  Endocrine       Date:  2008-10-30       Impact factor: 3.633

5.  Cellular uptake of proMMP-2:TIMP-2 complexes by the endocytic receptor megalin/LRP-2.

Authors:  Manuel Johanns; Pascale Lemoine; Virginie Janssens; Giuseppina Grieco; Soren K Moestrup; Rikke Nielsen; Erik I Christensen; Pierre J Courtoy; Hervé Emonard; Etienne Marbaix; Patrick Henriet
Journal:  Sci Rep       Date:  2017-06-28       Impact factor: 4.379

6.  Blocking matrix metalloproteinase-mediated syndecan-4 shedding restores the endothelial glycocalyx and glomerular filtration barrier function in early diabetic kidney disease.

Authors:  Raina D Ramnath; Matthew J Butler; Georgina Newman; Sara Desideri; Amy Russell; Abigail C Lay; Chris R Neal; Yan Qiu; Sarah Fawaz; Karen L Onions; Monica Gamez; Michael Crompton; Chris Michie; Natalie Finch; Richard J Coward; Gavin I Welsh; Rebecca R Foster; Simon C Satchell
Journal:  Kidney Int       Date:  2019-11-02       Impact factor: 10.612

7.  Effect of the Direct Renin Inhibitor Aliskiren on Urinary Albumin Excretion in Spontaneous Type 2 Diabetic KK-A (y) Mouse.

Authors:  Masako Furukawa; Tomohito Gohda; Shinji Hagiwara; Mitsuo Tanimoto; Satoshi Horikoshi; Kazuhiko Funabiki; Yasuhiko Tomino
Journal:  Int J Nephrol       Date:  2013-06-02

8.  Urinary matrix metalloproteinase activity in diabetic kidney disease: a potential marker of disease progression.

Authors:  Nagi Altemtam; Meguid El Nahas; Tim Johnson
Journal:  Nephron Extra       Date:  2012-08-09

9.  Plasma matrix metalloproteinases, low density lipoprotein oxidisability and soluble adhesion molecules after a glucose load in Type 2 diabetes.

Authors:  Mike Sampson; Isabel Davies; Jelena Gavrilovic; Brendan Sussams; Jackie Brown; Sian Astley; David A Hughes
Journal:  Cardiovasc Diabetol       Date:  2004-06-18       Impact factor: 9.951

10.  Vascular endothelial growth factor inhibition by dRK6 causes endothelial apoptosis, fibrosis, and inflammation in the heart via the Akt/eNOS axis in db/db mice.

Authors:  Cheol Whee Park; Hyung Wook Kim; Ji Hee Lim; Ki Dong Yoo; Sungjin Chung; Seok Joon Shin; Hyun Wha Chung; Sang Ju Lee; Chi-Bom Chae; Yong-Soo Kim; Yoon Sik Chang
Journal:  Diabetes       Date:  2009-08-12       Impact factor: 9.461
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.